Co-infection with feline retrovirus is related to changes in immunological parameters of cats with sporotrichosis

PLoS One. 2018 Nov 30;13(11):e0207644. doi: 10.1371/journal.pone.0207644. eCollection 2018.

Abstract

Feline sporotrichosis due to Sporothrix brasiliensis is frequently severe and often correlated to zoonotic transmission. Feline Immunodeficiency Virus (FIV) and Feline Leukemia Virus (FeLV) cause immunodeficiency in cats; no association has been identified with critical cases of sporotrichosis. Moreover, the cytokine profile in Sporothrix-infected cats and a potential impact of retrovirus co-infections on their immunity is unknown. This study assessed immunological parameters in cats with sporotrichosis with and without FIV or FeLV co-infection. FeLV infection was detected by antigen ELISA and by provirus PCR. FIV infection was investigated through ELISA and Western blot. Cytokine transcription (IFN-γ, IL-4, IL-5, IL-6, IL-10, IL-12, TNF-α) was quantified using RT-qPCR and lymphocyte subpopulations (CD4, CD8, CD5 and CD21) were assessed by flow cytometry. Thirty cats with sporotrichosis were recruited to the study, including three FIV-positive and five FeLV-positive (progressive infection) cats. One cat with regressive FeLV infection was excluded from statistics. In comparison to retrovirus-negative cats, FIV-positive cats and FeLV-positive cats had higher IL-10 levels, FeLV-positive cats had lower IL-4 levels and FIV-positive cats had lower IL-12 levels and a lower CD4+/CD8+ ratio. Remarkably, all cats with poor general condition were FeLV (progressive infection) or FIV-positive, but the retrovirus status was not associated with the sporotrichosis treatment length or outcome. The immunological changes and the more severe clinical presentation observed in cats with retrovirus co-infections encourage future prospective studies that address the impact of these changes on prognostic determinants of feline sporotrichosis and the development of new therapy strategies that control disease spread.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antifungal Agents / pharmacology
  • CD4-CD8 Ratio
  • Cats
  • Coinfection / immunology*
  • Coinfection / microbiology
  • Coinfection / virology
  • Cytokines / genetics
  • Cytokines / immunology
  • Cytokines / metabolism
  • Host-Pathogen Interactions / drug effects
  • Host-Pathogen Interactions / immunology
  • Immunodeficiency Virus, Feline / drug effects
  • Immunodeficiency Virus, Feline / immunology*
  • Immunodeficiency Virus, Feline / physiology
  • Itraconazole / pharmacology
  • Leukemia Virus, Feline / drug effects
  • Leukemia Virus, Feline / immunology*
  • Leukemia Virus, Feline / physiology
  • Lymphocyte Subsets / immunology
  • Lymphocyte Subsets / microbiology
  • Lymphocyte Subsets / virology
  • Potassium Iodide / pharmacology
  • Retroviridae Infections / drug therapy
  • Retroviridae Infections / immunology*
  • Retroviridae Infections / virology
  • Sporothrix / drug effects
  • Sporothrix / immunology*
  • Sporothrix / physiology
  • Sporotrichosis / drug therapy
  • Sporotrichosis / immunology*
  • Sporotrichosis / microbiology

Substances

  • Antifungal Agents
  • Cytokines
  • Potassium Iodide
  • Itraconazole

Grants and funding

Financial Disclosure: Part of the laboratory work was performed using logistics at the Center for Clinical Studies, Vetsuisse Faculty, University of Zürich. LHMM was a postdoctoral fellow with financial support from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES [Programa Estágio Pós-Doutoral/BEX, No 3229/13-0] and is currently a research fellow with financial support from CAPES [Programa Jovens Talentos, No 88887.091508/2014-00]. This study is part of a collaborative project Switzerland-Brazil (Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro - FAPERJ/ Swiss National Science Foundation - SNSF/ Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq nº 400064/2017-0) and was partially funded by FAPERJ [JCNE E-26/203.303/2016] and by Oswaldo Cruz Institute, Oswaldo Cruz Foundation [PAEF-IOC-008-FIO-15]. RCM and SAO are recipients of productivity fellowships from the CNPq